Federal Update: Psychedelic Policy Review Demanded By Congressional Principals, Here's What's Happening

The most recent report for the Commerce, Justice, Science, and Related Agencies (CSJ) produced by the House of Committee on Appropriations includes a novel section concerning psilocybin, where it demands a Government Accountability Office (GAO) analysis concerning state, local and tribal psilocybin programs’ limits

The increasing psychedelic reform movement in both local and state legislatures has triggered the request for a report to consider the impact of the federal Controlled Substances Act (CSA) enforcement in jurisdictions with programs that incorporate psilocybin products whether for therapeutic use or as part of religious, Indigenous, or spiritual practices. 

More specifically, “The report shall: (1) review the impact of Controlled Substances Act enforcement on psilocybin use legally sanctioned by States, local governments, and Tribes; (2) identify barriers to accessing therapeutic use of psilocybin in States that have made such use legal under State law; (3) recommend ways to improve the processes used to obtain Federal authorization to conduct research with psilocybin-related substances; and (4) identify barriers to legal access to and use of psilocybin for religious, Indigenous, or spiritual practices under the Religious Freedom Restoration Act.”

Last week, the same Committee also released spending bills and reports which, among other issues, called for investigations into alternative treatments including psychedelics for PTSD, as reported by Marijuana Moment

It is still uncertain whether the Senate will accept any of the House-led drug policy proposals. On the other hand, Senate appropriators have not yet published their spending bills for Fiscal Year 2023, usually waiting for the House to enact them first. So which issues get passed in both chambers and are eventually adopted into law remains unclear.

Photo Courtesy of Elihaj Mears on Unsplash.

Posted In: Congress Fiscal Year 2023CSAGovernment Accountability OfficeCannabisNewsPsychedelicsPoliticsLegalMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.